Article Details

Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings

Retrieved on: 2021-12-13 17:04:38

Tags for this article:

Click the tags to see associated articles and topics

Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings. View article details on hiswai:

Excerpt

Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, ...

Article found on: finance.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up